ES2190373A1 - Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero. - Google Patents

Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.

Info

Publication number
ES2190373A1
ES2190373A1 ES200102725A ES200102725A ES2190373A1 ES 2190373 A1 ES2190373 A1 ES 2190373A1 ES 200102725 A ES200102725 A ES 200102725A ES 200102725 A ES200102725 A ES 200102725A ES 2190373 A1 ES2190373 A1 ES 2190373A1
Authority
ES
Spain
Prior art keywords
acetyloxy
hydroxy
prevention
treatment
cognitive impairment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200102725A
Other languages
English (en)
Other versions
ES2190373B1 (es
Inventor
Rafanell Julian Garcia
Orti Genis Munoz
Ramirez Jose Carlos Navas
Pulido Jose Ignacio Izquierdo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noucor Health SA
Original Assignee
J Uriach y Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200102725A priority Critical patent/ES2190373B1/es
Application filed by J Uriach y Cia SA filed Critical J Uriach y Cia SA
Priority to US10/313,498 priority patent/US20030162756A1/en
Priority to CA002471794A priority patent/CA2471794A1/en
Priority to EP02787920A priority patent/EP1453499A1/en
Priority to KR1020047008791A priority patent/KR20050044742A/ko
Priority to ARP020104736A priority patent/AR037728A1/es
Priority to JP2003548818A priority patent/JP2005515993A/ja
Priority to MXPA04005450A priority patent/MXPA04005450A/es
Priority to AU2002352228A priority patent/AU2002352228A1/en
Priority to PCT/EP2002/013862 priority patent/WO2003047562A1/en
Priority to BR0214779-3A priority patent/BR0214779A/pt
Publication of ES2190373A1 publication Critical patent/ES2190373A1/es
Priority to NO20042785A priority patent/NO20042785L/no
Application granted granted Critical
Publication of ES2190373B1 publication Critical patent/ES2190373B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere al uso del ácido 2-hidroxi- o 2- acetiloxi-4-trifluorometilbenzoico, respectivamente, para el tratamiento o prevención del deterioro cognitivo ligero (DCL) en mamíferos, especialmente en seres humanos. Asimismo, la presente invención se refiere también al uso del ácido 2-hidroxi- ó 2- acetiloxi-4-trifluorometilbenzoico, respectivamente, para retrasar o prevenir la conversión de DCL a demencia, especialmente a enfermedad de Alzheimer.
ES200102725A 2001-12-07 2001-12-07 Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero. Expired - Fee Related ES2190373B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200102725A ES2190373B1 (es) 2001-12-07 2001-12-07 Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
AU2002352228A AU2002352228A1 (en) 2001-12-07 2002-12-06 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
EP02787920A EP1453499A1 (en) 2001-12-07 2002-12-06 Use of 2-hydroxy or 2-acetyloxy-4-trifluoro-methylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
KR1020047008791A KR20050044742A (ko) 2001-12-07 2002-12-06 경증 인식 장애의 치료제 및 예방제로서의 2-하이드록시또는 2-아세틸옥시-4-트리플루오로메틸벤조산 유도체의이용 방법
ARP020104736A AR037728A1 (es) 2001-12-07 2002-12-06 Un compuesto acido 2-hidroxi- o 2-acetiloxi-4-trifluoremetilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero
JP2003548818A JP2005515993A (ja) 2001-12-07 2002-12-06 軽度認識障害の治療及び予防剤としての２−ヒドロキシ又は２−アセチルオキシ−４−トリフルオロメチル安息香酸誘導体の使用
US10/313,498 US20030162756A1 (en) 2001-12-07 2002-12-06 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
CA002471794A CA2471794A1 (en) 2001-12-07 2002-12-06 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
PCT/EP2002/013862 WO2003047562A1 (en) 2001-12-07 2002-12-06 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
BR0214779-3A BR0214779A (pt) 2001-12-07 2002-12-06 Uso de derivados de acido 2-hidróxi ou 2-acetilóxi-4trifluormetilbenzóico como um agente para o tratamento e a prevenção de deterioração cognitiva moderada
MXPA04005450A MXPA04005450A (es) 2001-12-07 2002-12-06 Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agentes para el tratamiento y prevencion del deterioro cognitivo ligero.
NO20042785A NO20042785L (no) 2001-12-07 2004-07-01 Anvendelse av 2-hydroksy- eller 2-acetyloksy-4-trifluormetylbenzosyrederivater som et middel for behandlingen og forebyggingen av mild kognitiv svekkelse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200102725A ES2190373B1 (es) 2001-12-07 2001-12-07 Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.

Publications (2)

Publication Number Publication Date
ES2190373A1 true ES2190373A1 (es) 2003-07-16
ES2190373B1 ES2190373B1 (es) 2004-10-16

Family

ID=8499682

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200102725A Expired - Fee Related ES2190373B1 (es) 2001-12-07 2001-12-07 Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.

Country Status (12)

Country Link
US (1) US20030162756A1 (es)
EP (1) EP1453499A1 (es)
JP (1) JP2005515993A (es)
KR (1) KR20050044742A (es)
AR (1) AR037728A1 (es)
AU (1) AU2002352228A1 (es)
BR (1) BR0214779A (es)
CA (1) CA2471794A1 (es)
ES (1) ES2190373B1 (es)
MX (1) MXPA04005450A (es)
NO (1) NO20042785L (es)
WO (1) WO2003047562A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
JP5660037B2 (ja) * 2009-05-18 2015-01-28 Jsr株式会社 感放射線性樹脂組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061030A1 (es) * 1998-05-27 1999-12-02 J. Uriach & Cia, S.A. USO DE DERIVADOS DEL ACIDO 2-HIDROXI-4-TRIFLUOROMETILBENZOICO COMO INHIBIDORES DE LA ACTIVACION DEL FACTOR DE TRANSCRIPCION NUCLEAR NF-λB

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096252A (en) * 1976-06-10 1978-06-20 J. Uriach & Cia S.A. 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061030A1 (es) * 1998-05-27 1999-12-02 J. Uriach & Cia, S.A. USO DE DERIVADOS DEL ACIDO 2-HIDROXI-4-TRIFLUOROMETILBENZOICO COMO INHIBIDORES DE LA ACTIVACION DEL FACTOR DE TRANSCRIPCION NUCLEAR NF-λB

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LËPEZ-POUSA, S. y col. Triflusal en la prevención de la demencia vascular. Rev. Neurol., 1997, Vol. 25, Nö 146, páginas 1525-1528. Todo el documento, en especial, resumen y Discusión (página 1527). *

Also Published As

Publication number Publication date
JP2005515993A (ja) 2005-06-02
EP1453499A1 (en) 2004-09-08
KR20050044742A (ko) 2005-05-12
ES2190373B1 (es) 2004-10-16
AR037728A1 (es) 2004-12-01
AU2002352228A1 (en) 2003-06-17
CA2471794A1 (en) 2003-06-12
MXPA04005450A (es) 2005-04-19
US20030162756A1 (en) 2003-08-28
WO2003047562A1 (en) 2003-06-12
BR0214779A (pt) 2004-11-09
NO20042785L (no) 2004-07-01

Similar Documents

Publication Publication Date Title
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
GB0225475D0 (en) Therapeutic agents
GB0025173D0 (en) Therapeutic agents
GB0108592D0 (en) Therapeutic agents
EP1767197A3 (en) Treatment of Alzheimer's disease with inhibitors of cell cycle re-entry and progression
HK1037861A1 (en) Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention
GB2288732B (en) Pharmaceutical compositions
WO1998020864A3 (en) Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
AU2003220096A8 (en) Methods for alzheimer's disease treatment and cognitive enhancement
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
HK1043019A1 (en) Compositions and methods for prevention and treatment of protozoal disease.
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
RS8504A (en) Novel cyclohexil sulphones
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HUP0104963A3 (en) Compositions for the treatment of skin diseases
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
ES2190373A1 (es) Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
PL377110A1 (pl) Zapobieganie i leczenie choroby Alzheimera
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001016319A3 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030716

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2190373B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180803

FD2A Announcement of lapse in spain

Effective date: 20180807